BRPI1008230A2 - " peptídeo de penetração celular e composições farmacêuticas " - Google Patents

" peptídeo de penetração celular e composições farmacêuticas "

Info

Publication number
BRPI1008230A2
BRPI1008230A2 BRPI1008230A BRPI1008230A BRPI1008230A2 BR PI1008230 A2 BRPI1008230 A2 BR PI1008230A2 BR PI1008230 A BRPI1008230 A BR PI1008230A BR PI1008230 A BRPI1008230 A BR PI1008230A BR PI1008230 A2 BRPI1008230 A2 BR PI1008230A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
cell penetration
penetration peptide
peptide
cell
Prior art date
Application number
BRPI1008230A
Other languages
English (en)
Inventor
Kozo Takayama
Mariko Morishita
Nobuo Ida
Reiji Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI1008230A2 publication Critical patent/BRPI1008230A2/pt
Publication of BRPI1008230B1 publication Critical patent/BRPI1008230B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008230-1A 2009-05-20 2010-05-19 Peptídeo de penetração celular e composição farmacêutica BRPI1008230B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009122096 2009-05-20
JPJP2009-122096 2009-05-20
JP2010071774 2010-03-26
JPJP2010-071774 2010-03-26
PCT/JP2010/058420 WO2010134537A1 (ja) 2009-05-20 2010-05-19 細胞膜透過性ペプチド

Publications (2)

Publication Number Publication Date
BRPI1008230A2 true BRPI1008230A2 (pt) 2016-03-08
BRPI1008230B1 BRPI1008230B1 (pt) 2019-05-28

Family

ID=43126214

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008230-1A BRPI1008230B1 (pt) 2009-05-20 2010-05-19 Peptídeo de penetração celular e composição farmacêutica

Country Status (13)

Country Link
US (1) US8772449B2 (pt)
EP (1) EP2433953B1 (pt)
JP (1) JP5653214B2 (pt)
KR (1) KR101783291B1 (pt)
CN (1) CN102428096B (pt)
AU (1) AU2010250452B2 (pt)
BR (1) BRPI1008230B1 (pt)
CA (1) CA2762551C (pt)
ES (1) ES2546304T3 (pt)
MX (1) MX2011011960A (pt)
PL (1) PL2433953T3 (pt)
RU (1) RU2548807C2 (pt)
WO (1) WO2010134537A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016123578A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
CN108348572B (zh) * 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2017127567A1 (en) * 2016-01-19 2017-07-27 Genebiologics, Llc Production of arginine-rich proteins and use as a fertilizer and germination enhancer
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN110139870B (zh) * 2016-12-16 2023-12-01 爱维斯健有限公司 细胞膜穿透肽及包含其的细胞内输送载体
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP2019099578A (ja) * 2017-12-06 2019-06-24 参天製薬株式会社 細胞膜透過性ペプチドを含有する眼科用医薬組成物
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
CN109575107B (zh) * 2018-11-26 2022-03-08 上海华新生物高技术有限公司 一种细胞穿透肽及可表达口服干扰素的双歧杆菌
JP6932340B2 (ja) 2019-06-21 2021-09-08 滋 天野 細胞透過性ペプチド
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4210680A1 (en) 2020-09-07 2023-07-19 Cyprumed GmbH Improved pharmaceutical formulations of glp-1 receptor agonists
KR20230090333A (ko) 2020-10-16 2023-06-21 각코호우징 조쇼 가쿠엔 조성물
CN114805593A (zh) * 2021-01-19 2022-07-29 盛世泰研(广东)健康科技有限公司 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用
KR20220157778A (ko) * 2021-05-21 2022-11-29 원큐어젠 주식회사 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체
JP2025508982A (ja) 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
CN114984193A (zh) * 2022-06-07 2022-09-02 盛世泰研(广东)健康科技有限公司 一种psf-sod1与透明质酸的组合物及其制备方法与应用
CN115944713A (zh) * 2022-12-27 2023-04-11 中国人民解放军军事科学院军事医学研究院 一种神经营养因子和穿透肽组合物及其应用
JP7723457B2 (ja) * 2023-07-03 2025-08-14 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
WO2026034435A1 (ja) * 2024-08-09 2026-02-12 東亞合成株式会社 ペプチドフラグメント及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
AU766489B2 (en) * 1998-11-13 2003-10-16 Cyclacel Limited Transport vectors
JPWO2004037859A1 (ja) 2002-10-11 2006-02-23 株式会社三和化学研究所 Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
JP2005185271A (ja) * 2003-12-03 2005-07-14 Credia Japan:Kk 膜透過性ペプチド核酸
DK1814913T3 (en) * 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
CA2716565C (en) * 2008-02-28 2017-09-12 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法

Also Published As

Publication number Publication date
BRPI1008230B1 (pt) 2019-05-28
CA2762551C (en) 2016-11-22
WO2010134537A1 (ja) 2010-11-25
MX2011011960A (es) 2011-12-06
KR20120064650A (ko) 2012-06-19
PL2433953T3 (pl) 2015-12-31
AU2010250452B2 (en) 2014-06-05
US8772449B2 (en) 2014-07-08
RU2011151877A (ru) 2013-06-27
AU2010250452A1 (en) 2011-11-10
CN102428096B (zh) 2015-03-25
US20120065124A1 (en) 2012-03-15
EP2433953B1 (en) 2015-07-08
ES2546304T3 (es) 2015-09-22
EP2433953A4 (en) 2013-06-05
JPWO2010134537A1 (ja) 2012-11-12
CA2762551A1 (en) 2010-11-25
JP5653214B2 (ja) 2015-01-14
CN102428096A (zh) 2012-04-25
RU2548807C2 (ru) 2015-04-20
EP2433953A1 (en) 2012-03-28
KR101783291B1 (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
BRPI1008230A2 (pt) " peptídeo de penetração celular e composições farmacêuticas "
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
LTPA2018014I1 (lt) Farmacinė kompozicija 514
IL221278B (en) Chlorotoxin polypeptides and conjugates and uses thereof
BRPI0906722A2 (pt) Métodos e composições usando polipeptídeos de fusão klotho-fgf
BRPI0924137A2 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
DK3178835T3 (da) Forlængede rekombinante polypeptider og sammensætninger omfattende samme
PL3178490T3 (pl) Kompozycje białka f rsv i sposoby ich wytwarzania
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
EP2316414A4 (en) HAIR CARE COMPOSITION
HRP20151135T4 (hr) Novi i snažni peptidi mhc klase ii dobiveni od survivina
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0911743A2 (pt) "peptídeo"
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
BRPI0822221A2 (pt) Composições aquosas e estáveis de ciclosporina
PT3834841T (pt) Formulações de adamts13 líquidas e liofilizadas estabilizadas
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
PL2154966T3 (pl) Benzoimidazole i ich kompozycje farmaceutyczne
BRPI0908132A2 (pt) Composto de benzodiazepina e composição farmacêutica
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
BRPI1007194A2 (pt) Composição compreendendo ácido chicórico e/ou derivados do mesmo
BRPI1006666A2 (pt) " composição farmacêutica e uso de uma composição farmacêutica"
BRPI1011314A2 (pt) conjugados de albumina-peptídeo amilóide e usos dos mesmos
EP2300033A4 (en) CONJUGATES OF COLLAGEN PEPTIDE AND USES THEREOF

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.